FILSPARI indicated to reduce proteinuria in adults and children aged 8 years and older with FSGS who do not have nephrotic syndrome. Additional indication for FILSPARI expands tot ...

Food and Drug Administration has approved the ‌expanded use of Travere Therapeutics' ‌drug to treat a rare kidney disorder, ...

Monday’s FDA approval makes Filspari the first therapy specifically indicated for FSGS, a condition that represents a $1 ...

The U.S. Food and Drug Administration has approved the expanded use of ​Travere Therapeutics' drug to treat a rare kidney ...

Travere Therapeutics, Inc. ( TVTX) Discusses FDA Approval of FILSPARI as First Approved Medicine for FSGS April 13, 2026 6:45 PM EDT ...

Travere Therapeutics received approval from the Food and Drug Administration for a treatment for a rare kidney disorder. The biopharmaceutical company said Monday the approval is for its Filspari drug ...

The agency approved the drug in adult and pediatric patients aged 8 years and older. ・Travere expects that there are at least 30,000 people in the U.S. with focal segmental glomerulosclerosis but ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

ROCKVILLE, Md., April 13, 2026 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) announced today its 2026 Class of Corporate Members who serve as strategic partners in AKF's Corporate Membership ...

More than half of UK business leaders are unprepared for threats posed by advanced AI-powered cyber threats, according to new research from Hornetsecurity by Proofpoint, a leading cybersecurity firm.

Pacsun, the purpose-driven specialty fashion retailer rooted in youth culture, activated across the desert this past weekend with a series of experiences reflecting the intersection of music, fashion, ...